Literature DB >> 17056636

Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.

Martin Zenker1, Katarina Lehmann, Anna Leana Schulz, Helmut Barth, Dagmar Hansmann, Rainer Koenig, Rudolf Korinthenberg, Martina Kreiss-Nachtsheim, Peter Meinecke, Susanne Morlot, Stefan Mundlos, Anne S Quante, Salmo Raskin, Dirk Schnabel, Lars-Erik Wehner, Christian P Kratz, Denise Horn, Kerstin Kutsche.   

Abstract

BACKGROUND: Noonan syndrome, cardio-facio-cutaneous syndrome (CFC) and Costello syndrome constitute a group of developmental disorders with an overlapping pattern of congenital anomalies. Each of these conditions can be caused by germline mutations in key components of the highly conserved Ras-MAPK pathway, possibly reflecting a similar pathogenesis underlying the three disorders. Germline mutations in KRAS have recently been identified in a small number of patients with Noonan syndrome and CFC. METHODS AND
RESULTS: 260 patients were screened for KRAS mutations by direct sequencing. Overall, we detected KRAS mutations in 12 patients, including three known and eight novel sequence alterations. All mutations are predicted to cause single amino acid substitutions. Remarkably, our cohort of individuals with KRAS mutations showed a high clinical variability, ranging from Noonan syndrome to CFC, and also included two patients who met the clinical criteria of Costello syndrome.
CONCLUSION: Our findings reinforce the picture of a clustered distribution of disease associated KRAS germline alterations. We further defined the phenotypic spectrum associated with KRAS missense mutations and provided the first evidence of clinical differences in patients with KRAS mutations compared with Noonan syndrome affected individuals with heterozygous PTPN11 mutations and CFC patients carrying a BRAF, MEK1 or MEK1 alteration, respectively. We speculate that the observed phenotypic variability may be related, at least in part, to specific genotypes and possibly reflects the central role of K-Ras in a number of different signalling pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056636      PMCID: PMC2598066          DOI: 10.1136/jmg.2006.046300

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  32 in total

Review 1.  Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome.

Authors:  D Wieczorek; F Majewski; G Gillessen-Kaesbach
Journal:  Clin Genet       Date:  1997-07       Impact factor: 4.438

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 3.  Tumor predisposition in Costello syndrome.

Authors:  Karen W Gripp
Journal:  Am J Med Genet C Semin Med Genet       Date:  2005-08-15       Impact factor: 3.908

Review 4.  Noonan syndrome.

Authors:  J E Allanson
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

5.  Clinical and molecular studies in a large Dutch family with Noonan syndrome.

Authors:  I van der Burgt; E Berends; E Lommen; S van Beersum; B Hamel; E Mariman
Journal:  Am J Med Genet       Date:  1994-11-01

Review 6.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

7.  Biological and structural characterization of a Ras transforming mutation at the phenylalanine-156 residue, which is conserved in all members of the Ras superfamily.

Authors:  L A Quilliam; S Zhong; K M Rabun; J W Carpenter; T L South; C J Der; S Campbell-Burk
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Probing the role of loop 2 in Ras function with unnatural amino acids.

Authors:  H H Chung; D R Benson; V W Cornish; P G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  BRAF and KRAS mutations in stomach cancer.

Authors:  Sug Hyung Lee; Jong Woo Lee; Young Hwa Soung; Hong Sug Kim; Won Sang Park; Su Young Kim; Jong Heun Lee; Jik Young Park; Yong Gu Cho; Chang Jae Kim; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo
Journal:  Oncogene       Date:  2003-10-09       Impact factor: 9.867

10.  Effector domain mutations dissociate p21ras effector function and GTPase-activating protein interaction.

Authors:  J C Stone; M Colleton; D Bottorff
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

View more
  70 in total

1.  Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer.

Authors:  Alenka Ličar; Petra Cerkovnik; Srdjan Novaković
Journal:  Med Oncol       Date:  2010-07-20       Impact factor: 3.064

2.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 3.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

4.  Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.

Authors:  Masako Yaoita; Tetsuya Niihori; Seiji Mizuno; Nobuhiko Okamoto; Shion Hayashi; Atsushi Watanabe; Masato Yokozawa; Hiroshi Suzumura; Akihiko Nakahara; Yusuke Nakano; Tatsunori Hokosaki; Ayumi Ohmori; Hirofumi Sawada; Ohsuke Migita; Aya Mima; Pablo Lapunzina; Fernando Santos-Simarro; Sixto García-Miñaúr; Tsutomu Ogata; Hiroshi Kawame; Kenji Kurosawa; Hirofumi Ohashi; Shin-Ichi Inoue; Yoichi Matsubara; Shigeo Kure; Yoko Aoki
Journal:  Hum Genet       Date:  2015-12-29       Impact factor: 4.132

5.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

6.  Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Authors:  Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

7.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.

Authors:  Karen W Gripp; Katia Sol-Church; Patroula Smpokou; Gail E Graham; David A Stevenson; Heather Hanson; David H Viskochil; Laura C Baker; Bridget Russo; Nick Gardner; Deborah L Stabley; Verena Kolbe; Georg Rosenberger
Journal:  Am J Med Genet A       Date:  2015-04-25       Impact factor: 2.802

Review 9.  Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature.

Authors:  Fu-Sung Lo; Ju-Li Lin; Min-Tzu Kuo; Pao-Chin Chiu; San-Ging Shu; Mei-Chyn Chao; Yann-Jinn Lee; Shuan-Pei Lin
Journal:  Eur J Pediatr       Date:  2008-10-29       Impact factor: 3.183

Review 10.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.